<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397029</url>
  </required_header>
  <id_info>
    <org_study_id>GW10029</org_study_id>
    <nct_id>NCT04397029</nct_id>
  </id_info>
  <brief_title>Assessing the Sensitivity of &quot;SureTouch™&quot; in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography</brief_title>
  <official_title>Assessing the Sensitivity of &quot;SureTouch™&quot; in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebecca Kaltman, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sure, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, case-control study being conducted to determine the sensitivity of the SureTouch
      device in detecting known masses at a pre-determined level of specificity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, case-control study being conducted to determine the
      sensitivity of the SureTouch device in detecting known masses at a pre-determined level of
      specificity.

      Results of the mammography will be compared to the SureTouch examination results.

      Subjects will have between 1 and 3 research visits and 3 follow-up surveys, up to two years
      from the initial visit. The number of visits will be based upon comparison of the SureTouch
      examination to conventional breast screening techniques (mammogram and ultrasound).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary</measure>
    <time_frame>2 years</time_frame>
    <description>1. This study examines the sensitivity of the SureTouch™ system, compared with methods that are the current standard of care (screening and diagnostic mammography with ultrasound), to detect clinically significant mass lesions in the breast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary</measure>
    <time_frame>2 years</time_frame>
    <description>The study will determine the patient acceptance of and satisfaction with the SureTouch devise. Outcome measure will use a 9 question Likert scale survey to assess patient perception of the comfort, duration and acceptance of the SureTouch device.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Subjects without messes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are believed to be free of masses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with known masses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with known masses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SureTouch</intervention_name>
    <description>The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.
The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.
Both groups will receive breast cancer screening with mammography and SureTouch.</description>
    <arm_group_label>Subjects with known masses</arm_group_label>
    <arm_group_label>Subjects without messes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Arm 1:

          -  Female Subject presenting for screening mammography

          -  30-80 years of age, inclusive

          -  Able to provide written informed consent

        Arm 2:

          -  Female Subject presenting for diagnostic appointment and/or biopsy

          -  30-80 years of age, inclusive

          -  1-3 masses per breast

          -  Masses between 0.5 cm and 3.5 cm only

        Exclusion Criteria:

          -  Individuals who are unable to comprehend or unwilling to sign an informed consent form

          -  Women younger than 30 or older than 80

          -  Pregnant women

          -  Women who have undergone bilateral mastectomies

          -  Males

          -  Prisoners

          -  Masses which are larger than 3.5 cm or smaller than 0.5 cm in size

          -  Individuals with more than 3 masses per breast will be excluded due to the complexity
             of these cases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christiane Morecock</last_name>
    <phone>202-655-5955</phone>
    <email>cmorecock@mfa.gwu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>George Washington University - Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Morecock</last_name>
      <phone>202-655-5955</phone>
      <email>cmorecock@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Anita Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cancer Stat Facts: Female Breast Cancer. Surveillance, Epidemiology, and End Results Program (SEER). https://seer.cancer.gov/statfacts/html/breast.html#skipnav. Accessed July 2, 2018.</citation>
  </reference>
  <reference>
    <citation>National Center for Health Statistics (NCHS). Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville, MD. 2017.</citation>
  </reference>
  <reference>
    <citation>Chang JM, Park IA, Lee SH, Kim WH, Bae MS, Koo HR, Yi A, Kim SJ, Cho N, Moon WK. Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer. Eur Radiol. 2013 Sep;23(9):2450-8. doi: 10.1007/s00330-013-2866-2. Epub 2013 May 15.</citation>
    <PMID>23673574</PMID>
  </reference>
  <reference>
    <citation>Michaelson, James &amp; Satija, Sameer &amp; Moore, Richard &amp; Weber, Griffin &amp; Halpern, Elkan &amp; Garland, Andrew &amp; Kopans, Daniel &amp; Hughes, Kevin. (2003). Estimates of the Sizes at Which Breast Cancers Become Detectable on Mammographic and Clinical Grounds. Journal of Women's Imaging. 5. 10.1097/00130747-200302000-00002.</citation>
  </reference>
  <reference>
    <citation>Evans A, Whelehan P, Thomson K, McLean D, Brauer K, Purdie C, Jordan L, Baker L, Thompson A. Quantitative shear wave ultrasound elastography: initial experience in solid breast masses. Breast Cancer Res. 2010;12(6):R104. doi: 10.1186/bcr2787. Epub 2010 Dec 1.</citation>
    <PMID>21122101</PMID>
  </reference>
  <reference>
    <citation>Skovoroda, A.R., Klishko, A.N., Gusakyan, D.A., Mayevskii, Y.E., Yermilova, V.D.,Oranskaya, G.A. and Sarvazyan, A.P. 1995. Quantitative analysis of the mechanical characteristics of pathologically changed soft biological tissues. Biophsics, 40(6):1359-64.</citation>
  </reference>
  <reference>
    <citation>Krouskop TA, Wheeler TM, Kallel F, Garra BS, Hall T. Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging. 1998 Oct;20(4):260-74.</citation>
    <PMID>10197347</PMID>
  </reference>
  <reference>
    <citation>Sarvazyan A, Egorov V, Son JS, Kaufman CS. Cost-effective screening for breast cancer worldwide: current state and future directions. Breast Cancer (Auckl). 2008;1:91-9. Epub 2008 Jul 2.</citation>
    <PMID>19578481</PMID>
  </reference>
  <reference>
    <citation>Kaufman CS, Jacobson L, Bachman BA, Kaufman LB. Digital documentation of the physical examination: moving the clinical breast exam to the electronic medical record. Am J Surg. 2006 Oct;192(4):444-9.</citation>
    <PMID>16978946</PMID>
  </reference>
  <reference>
    <citation>Wellman PS, Dalton EP, Krag D, Kern KA, Howe RD. Tactile imaging of breast masses: first clinical report. Arch Surg. 2001 Feb;136(2):204-8.</citation>
    <PMID>11177142</PMID>
  </reference>
  <reference>
    <citation>Kaufman CS, et al., Objective measurement of the physical exam using a new device: reproducible triage of palpable masses. Breast Cancer Research and Treatment, 2004; 88; supp 1:S223-4- SABCS 2004.</citation>
  </reference>
  <reference>
    <citation>Kaufman CS, Son JS, Yered E, Sarvazyan A. Cancer Res May 1 2015 (75) (9 Supplement) P1- 02-09; DOI:10.1158/1538-7445.SABCS14-P1-02-09</citation>
  </reference>
  <reference>
    <citation>Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol. 2009 Oct;193(4):1124-7. doi: 10.2214/AJR.09.2520.</citation>
    <PMID>19770337</PMID>
  </reference>
  <reference>
    <citation>Heshmatzadeh Behzadi A, Farooq Z, Newhouse JH, Prince MR. MRI and CT contrast media extravasation: A systematic review. Medicine (Baltimore). 2018 Mar;97(9):e0055. doi: 10.1097/MD.0000000000010055. Review.</citation>
    <PMID>29489663</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Rebecca Kaltman, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Screening</keyword>
  <keyword>Elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

